** Shares of Proteomics International Labs rise as much as 8.4% to A$0.71
** The medical technology co says its PromarkerEso blood test for esophageal adenocarcinoma shows 94% accuracy in clinical validation study
** Co says esophageal adenocarcinoma, a cancer arising in the food pipe, is among the leading cause of cancer-related deaths, with a 5-year survival rate of 20%, due to late diagnosis
** Says improved surveillance of at-risk patients using PromarkerEso could enable earlier diagnosis and significantly improve health outcomes
** Stock has fallen 26.8% this year, as of last close
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。